Cutex products now available at extreme-value retailer Five Below
ST. LOUIS — Cutex has announced the availability of its Advanced Revival formula at Five Below retail stores across the United States.
As the retail store’s name suggests, Five Below is offering select Cutex products for less than $5. Nail polish remover products include the Advanced Revival One-Step Remover Pads, Advanced Revival Liquid Nail Polish Remover, the Cutex Corrector Pen and Cutex Regular Instant Nail Polish Remover Jar.
“Cutex always looks for innovative ways to reach a new loyal customer base, and partnering with Five Below is a great way to get Cutex products into and onto the hands of many consumers around the nation,” stated John Mandelker, president of Cutex. “We take pride in our 100-year legacy allowing us to break ground in the innovation of new and better products.”
The Cutex Advanced Revival formula is the first innovation in nail polish remover in more than 15 years. The patent-pending formula combines the power of acetone with strengthening and nourishing natural apricot seed and parilla drying oils, the company stated.
Cutex Advanced Revival Nail Polish Remover Pads use the same Advanced Revival formula but are able to condition nails and cuticles in one step. The patented formula is designed to remove polish faster and create an ideal canvas for a base coat or nail polish that follows. Each felt pad is individually wrapped and removes polish from 10 nails, fingers or toes.
Also available at Five Below are the Cutex Corrector Pen and the Cutex Regular Instant Nail Polish Remover Jar. The Corrector Pen combines the performance of Cutex nail polish remover with the precision of a contoured applicator tip for quick, accurate touch-ups. The pen includes four extra tips in a portable design. The Cutex Regular Instant Nail Polish Remover Jar is an alternative to liquid polish removers. Each nail is cleaned by twisting one finger at a time with the sponge in the jar.
AstraZeneca to buy developer of COPD drug
LONDON — Anglo-Swedish drug maker AstraZeneca will pay up to $1.15 billion for a U.S. developer of drugs for respiratory diseases, AstraZeneca said Monday.
The company announced that it would buy Redwood City, Calif.-based Pearl Therapeutics, which has an inhaled drug for chronic obstructive pulmonary disease, called PT003 (formoterol fumarate; glycopyrrolate), in late-stage clinical development.
Under the deal, AstraZeneca will buy 100% of shares in Pearl, including a $560 million initial payment, up to $450 million in development-related milestone payments and $140 million in payments related to potential product sales. The deal is expected to close in the summer.
"Chronic obstructive pulmonary disease continues to increase worldwide, and there is a growing need for the next generation of inhaled combination products," AstraZeneca CEO Pascal Soriot said. "Pearl’s novel formulation technology, together with its development products and specialist expertise, is a great complement to AstraZeneca’s long-established capabilities in respiratory disease, one of our core therapy areas."
Walgreens’ continued transformation into comprehensive health solutions provider is an opportunity for all
Beginning July 1, Walgreens will be able to provide tube feeding services to Medicare patients in 97 of 100 competitive-bidding areas nationwide, the healthcare solutions provider announced last week. The contracts are up for renewal every three years.
This is just another example of how Walgreens is transforming its pharmacy business into a center for healthcare solutions — this goes far beyond dispensing and ultimately aims squarely at reducing hospitalization costs, another way that Walgreens is helping payers bend the cost curve. It begs the question: Should traditional suppliers be thinking about the role their products can play as Walgreens develops new business segments like infusion services?
The underlying question is whether those patients — who may need nutrition information and possibly education on how to better manage a chronic condition — can make a difference to your business.
Approximately 40,000 PN patients and 344,000 EN patients each year receive their nutrition therapy at home.
Walgreens has certainly proven its services help generate positive outcomes. According to a joint release from Walgreens and the American Society for Parenteral and Enteral Nutrition issued earlier this year, Walgreens’ home nutrition support team interventions improved patient care and potentially prevented an estimated 429 hospital days over a three-month period. The cost savings of those interventions were estimated at more than $850,000.
The study included data from 16 Walgreens Infusion Services offices, with 2,500 enteral nutrition patients and 270 parenteral nutrition patients on service during the study period. Interventions were performed by the Walgreens Infusion Services home nutrition support team, which includes nurses, pharmacists and dietitians who work closely with physicians to provide care to both EN and PN patients.
The patient-centric multidisciplinary approach to care enabled the teams to identify therapy complications and intervene. There were 373 total interventions completed during the three-month study, including correcting over/underfeeding, preventing dehydration, reducing/eliminating diarrhea, managing hyperglycemia, managing electrolyte imbalances, transitioning patients from PN to oral eating, and starting patients on PN therapy in the home instead of in the hospital.